Anti-TNFalpha therapy improves survival and ameliorates the pathophysiologic sequelae in acute pancreatitis in the rat

Am J Surg. 1996 Feb;171(2):274-80. doi: 10.1016/s0002-9610(97)89568-2.

Abstract

Background: Elevated levels of tumor necrosis factor-alpha (TNFalpha) have been measured in a lethal model acute pancreatitis (AP) and may contribute to the pathophysiologic sequelae of the disease.

Methods: To determine the significance of anti-TNFalpha therapy on survival and disease manifestations in a clinically relevant model of AP, a rat model was developed using a retrograde pancreatic ductal infusion of bile. Animals were randomized to no treatment (n = 30) or treatment with anti-TNFalpha antibody 15 minutes prior to induction of AP (n = 30). Five treated and 5 untreated rats were killed at various time periods up to 72 hours to provide temporal characterization of TNFalpha activity in AP.

Results: A burst Of TNFalpha activity in the serum of untreated pancreatitis animals between 1 and 3 hours after induction of the disease is prevented by pretreatment with anti-TNFalpha antibody.

Conclusions: These findings provide a plausible mechanism for the improvement in biochemical and histologic parameters as well as in overall survival in an experimental model of acute pancreatitis in the rat.

MeSH terms

  • Acute Disease
  • Animals
  • Antibodies, Anti-Idiotypic / therapeutic use*
  • Disease Models, Animal
  • Male
  • Pancreatitis / drug therapy*
  • Pancreatitis / pathology
  • Pancreatitis / physiopathology
  • Rats
  • Rats, Sprague-Dawley
  • Tumor Necrosis Factor-alpha / analysis
  • Tumor Necrosis Factor-alpha / immunology*

Substances

  • Antibodies, Anti-Idiotypic
  • Tumor Necrosis Factor-alpha